FDA Approves First At-Home COVID and Flu Test for OTC Use

The FDA has granted marketing authorization for the Healgen Rapid Check COVID-19/Flu A&B Antigen Test, marking a significant milestone as the first over-the-counter test capable of detecting both COVID-19 and influenza without a prescription. The test, which provides results in approximately 15 minutes via a nasal swab, is notable for its high accuracy, with a 99% accuracy rate for negative COVID-19 cases and 92% for positive cases, alongside robust results for Flu A and B[1][2]. This authorization, conducted through a traditional premarket review rather than emergency use, establishes new special controls for labeling and performance, paving the way for the development of similar tests by streamlining the regulatory process[2].
References
Explore Further
How does the Healgen Rapid Check test compare to other at-home COVID-19 and flu tests in terms of accuracy and usability?
What are the potential challenges Healgen might face in scaling up production to meet the anticipated demand during flu season?
How might the availability of this test impact healthcare systems, particularly in terms of relieving pressure during peak flu periods?
Are there specific guidelines for individuals on when to use the test or seek medical advice if they suspect a false negative?
What implications does the FDA's traditional premarket review process for this test have on future OTC diagnostic tool developments?